Contents

Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization (CNV) in Age-related Macular Degeneration (ANCHOR)

January 1, 2009

Clinical Trial

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T.

Ophthalmology. 2009 Jan;116(1):57-65.e5.
Full text | Metrics.

Main finding: Ranibizumab provided greater clinical benefit than verteporfin PDT in patients with predominantly classic CNV secondary to AMD

 

  • Purpose: To compare ranibizumab with verteporfin photodynamic therapy in treating predominantly classic CNV
  • Study type: Randomized controlled trial
  • Condition: CNV secondary to AMD

Participants: Predominantly classic, subfoveal CNV

 

  • n=423

 

Intervention:

 

Group 1: Verteporfin PDT + sham injection
-PDT given on Day 0 then PRN q3monthly
Group 2: Sham PDT + Intravitreal Ranibizumab 0.3mg monthly
Group 3: Sham PDT + Intravitreal Ranibizumab 0.5mg monthly

Outcomes PDT RAN
Lost < 15 letters from baseline 65.7% 89.9-90.0%
Gained ≥ 15 letters 6.3% 34.0-41.0%
VA change (letters) -9.8 +8.1 to 10.7

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed